Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_provenance.
- NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_assertion description "[Activating mutations in the juxtamembrane domain (FLT3-length mutations, FLT3-LM) and in the protein tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD) represent the most frequent genetic alterations in acute myeloid leukemia (AML) and define a molecular target for therapeutic interventions by protein tyrosine kinase (PTK) inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_provenance.
- NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_assertion evidence source_evidence_literature NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_provenance.
- NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_assertion SIO_000772 14604974 NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_provenance.
- NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_assertion wasDerivedFrom befree-20150227 NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_provenance.
- NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_assertion wasGeneratedBy ECO_0000203 NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_provenance.
- befree-20150227 importedOn "2015-02-27" NP402047.RAPzWwSFvqB0-OL632q0GmJ2QJuJ1jH7WfCUwJyH47jL8130_provenance.